Experimental cocktail aims to silence Life-Threatening food allergies
NCT ID NCT06369467
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests two drugs together—linvoseltamab and dupilumab—in just 6 adults with severe food allergies. The goal is to see if the combination is safe and can lower IgE antibodies that trigger allergic reactions. Participants must have a history of anaphylaxis to foods like peanuts, milk, or shellfish. The trial focuses on safety and side effects, not yet on curing the allergy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
linvoseltamab and dupilumab
What this could lead to
If it works, this could point toward a way to reduce or eliminate severe allergic reactions to foods like peanuts, milk, and shellfish.
What could go wrong
This is a very early, tiny Phase 1 trial with only 6 people. It is primarily checking safety, not effectiveness. The combination may cause side effects or fail to reduce allergies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
University of South Florida
Tampa, Florida, 33613, United States